Emcure Pharmaceuticals Q4 FY26 Earnings Call Transcript Released
Emcure Pharmaceuticals reported Q4 FY26 results with revenue up 16.7% to ₹2,470 crores and full-year revenue at ₹9,204 crores (up 16.6%). Adjusted PAT grew 36% in Q4 to ₹279 crores and 41% for the full year to ₹1,008 crores. The company surpassed $1 billion in revenue for FY26. Key partnerships were formed with Novo Nordisk and Sanofi. FY27 revenue growth is projected at low to mid-teen.
The announcement provides a detailed update on financial performance, strategic initiatives, and future outlook. While positive, it does not include immediate, drastic changes that would significantly alter the company's market position or valuation in the short term.
The company reported strong financial results, exceeding revenue and profit guidance, with significant year-on-year growth in both quarterly and annual figures. Strategic partnerships and pipeline advancements were also highlighted, contributing to a positive outlook.
Emcure Pharmaceuticals Limited has released the transcript of its Earnings Call for Q4 FY26, which was held on Tuesday, May 05, 2026, at 03:30 p.m. (IST). The transcript is also available on the company's website.
During the call, Managing Director & CEO, Mr. Satish Mehta, highlighted that FY26 marked the start of their 5-year strategy, with the company surpassing $1 billion in revenue, achieving 16.6% year-on-year growth. Base business EBITDA margins increased by over 100 basis points, and adjusted PAT grew more than 40%. Key strategic highlights included portfolio expansion through in-licensing, M&A, and internal R&D. Notable partnerships were formed with Novo Nordisk for Poviztra, Sanofi for oral anti-diabetic brands Amaryl & Cetapin, and Roche for select nephrology and transplant medications. The company also completed a minority stake buyout in Zuventus and acquired portfolios in the UK and Canada.
In R&D, Amphotericin B was launched in select European markets, with plans for further expansion. Bevacizumab, an ophthalmic biosimilar, received endorsement and is planned for launch in H1 FY27. Emcure also became a global voluntary licensee for Gilead's Lenacapavir.
Financially, for Q4 FY26, revenue from operations grew by 16.7% to ₹2,470 crores. International markets showed strong growth, with revenues increasing by 25.7% to ₹1,493 crores. EBITDA grew 24.5% to ₹485 crores, and reported PAT was ₹244 crores, with adjusted PAT at ₹279 crores (up 36% YoY). For the full year FY26, revenue grew 16.6% to ₹9,204 crores. EBITDA was ₹1,789 crores (up 21.8% YoY), and reported PAT was ₹941 crores, with adjusted PAT at ₹1,008 crores (up 41% YoY).
The company projects low to mid-teen revenue growth for FY27, with EBITDA margin expansion of 75 to 100 basis points, assuming stable regulatory and macroeconomic conditions. Management expressed optimism about future performance, emphasizing execution, science-driven innovation, and stakeholder value creation.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.